Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Endocrine Pathology
Published in: Endocrine Pathology 3/2010

01-09-2010

MGMT Immunoexpression in Silent Subtype 3 Pituitary Adenomas: Possible Therapeutic Implications

Authors: Michael E. Fealey, Bernd W. Scheithauer, Eva Horvath, Dana Erickson, Kalman Kovacs, Roger McLendon, Ricardo V. Lloyd

Published in: Endocrine Pathology | Issue 3/2010

Login to get access

Abstract

The objective of the study was to assess O 6-methylguanine-DNA methyltransferase (MGMT) immunoreactivity in pituitary adenomas of silent subtype 3 as a potential indicator of temozolomide susceptibility. The Mayo Clinic Anatomic Pathology Database was searched for all cases of silent subtype 3 pituitary adenoma. Each of the 23 cases identified had been confirmed on the basis of histology, immunohistochemical staining for pituitary hormones, as well as on diagnostic ultrastructural criteria. Unstained microscopic sections were immunostained for MGMT and were semiquantitatively assessed. Of the 23 tumors examined, 18 (78%) showed no MGMT immunoreactivity. The remaining five (22%) showed immunoreactivity in ≤50% of tumor cells. Among eight of the most clinically aggressive tumors in this study, six (75%) lacked MGMT immunoreactivity. The observed lack of or low-level expression of MGMT by this distinctive, clinically aggressive form of pituitary adenoma suggests potential efficacy of treatment with the alkylating agent temozolomide.
Literature
1.
Erickson D, Scheithauer B, Atkinson J, Horvath E, Kovacs K, Lloyd RV, Young WF, Jr.: Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience. Clin Endocrinol (Oxf) 71 (1):92-99, 2009.CrossRef
2.
Horvath E, Lloyd RV, Kovacs K, Sano T, Kontogeorgos G, Trouillas J, Asa SL (2004). Plurihormonal adenoma. In: RA De Lellis, RV Lloyd, PU Heitz et al. (eds) World Health Organization classification for tumours—pathology & genetics—tumours of endocrine organs. International Agency for Research on Cancer, Lyon, p 35.
3.
Horvath E, Kovacs K, Smyth HS, Killinger DW, Scheithauer BW, Randall R, Laws ER, Jr., Singer W: A novel type of pituitary adenoma: morphological features and clinical correlations. J Clin Endocrinol Metab 66 (6):1111-1118, 1988.CrossRefPubMed
4.
Lillehei KO, Kirschman DL, Kleinschmidt-DeMasters BK, Ridgway EC: Reassessment of the role of radiation therapy in the treatment of endocrine-inactive pituitary macroadenomas. Neurosurgery 43 (3):432-438; discussion 438-439, 1998.CrossRefPubMed
5.
Osamura RY, Kajiya H, Takei M, Egashira N, Tobita M, Takekoshi S, Teramoto A: Pathology of the human pituitary adenomas. Histochem Cell Biol 130 (3):495-507, 2008.CrossRefPubMed
6.
Biswas T, Ramana CV, Srinivasan G, Boldogh I, Hazra TK, Chen Z, Tano K, Thompson EB, Mitra S: Activation of human O6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone. Oncogene 18 (2):525-532, 1999.CrossRefPubMed
7.
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (10):997-1003, 2005.CrossRefPubMed
8.
Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD, Penagos LC: MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 115 (2):261-262, 2008.CrossRefPubMed
9.
Verbeek B, Southgate TD, Gilham DE, Margison GP: O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. Br Med Bull 85:17-33, 2008.CrossRefPubMed
10.
Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE: Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Hum Pathol 38 (1):185-189, 2007.CrossRefPubMed
11.
Moyes VJ, Alusi G, Sabin HI, Evanson J, Berney DM, Kovacs K, Monson JP, Plowman PN, Drake WM: Treatment of Nelson's syndrome with temozolomide. Eur J Endocrinol 160 (1):115-119, 2009.CrossRefPubMed
12.
Kouwenhoven MC, Kros JM, French PJ, Biemond-ter Stege EM, Graveland WJ, Taphoorn MJ, Brandes AA, van den Bent MJ: 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer 42 (15):2499-2503, 2006.CrossRefPubMed
13.
Soffietti R, Leoncini B, Ruda R: New developments in the treatment of malignant gliomas. Expert Rev Neurother 7 (10):1313-1326, 2007.CrossRefPubMed
14.
Horvath E, Kovacs K, Smyth HS, Cusimano M, Singer W: Silent adenoma subtype 3 of the pituitary--immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol 29 (6):511-524, 2005.CrossRefPubMed
15.
Horvath E, Kovacs K, Killinger DW, Smyth HS, Platts ME, Singer W: Silent corticotropic adenomas of the human pituitary gland: a histologic, immunocytologic, and ultrastructural study. Am J Pathol 98 (3):617-638, 1980.PubMed
16.
Karavitaki N, Ansorge O, Wass JA: Silent corticotroph adenomas. Arq Bras Endocrinol Metabol 51 (8):1314-1318, 2007.PubMed
17.
Trouillas J, Barkan AL, Watson RE, Jr., Lindell EP, Farrell WE, Lloyd RV. ACTH producing adenoma. In: World Health Organization Classification for Tumours - Pathology & Genetics - Tumours of Endocrine Organs. RA De Lellis; RV Lloyd; PU Heitz et al., editors. Lyon, France: International Agency for Research on Cancer; 2004; p. 26-29.
18.
Lloyd RV, Kovacs K, Young WF, Jr., Farrell WE, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheithauer BW, Horvath E. Pituitary tumours: Introduction. In: World Health Organization Classification for Tumours - Pathology & Genetics - Tumours of Endocrine Organs. RA De Lellis; RV Lloyd; PU Heitz et al., editors. Lyon, France: International Agency for Research on Cancer; 2004; p. 10-13.
19.
Mohammed S, Syro L, Abad V, Salehi F, Horvath E, Scheithauer BW, Kovacs K, Cusimano M: Silent somatotroph adenoma of the pituitary in an adolescent. Can J Neurol Sci 36 (1):123-125, 2009.PubMed
20.
Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E, Kovacs K: Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) 65 (4):552-553, 2006.CrossRef
Metadata
Title
MGMT Immunoexpression in Silent Subtype 3 Pituitary Adenomas: Possible Therapeutic Implications
Authors
Michael E. Fealey
Bernd W. Scheithauer
Eva Horvath
Dana Erickson
Kalman Kovacs
Roger McLendon
Ricardo V. Lloyd
Publication date
01-09-2010
Publisher
Springer US
Published in
Endocrine Pathology / Issue 3/2010
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-010-9120-0

Other articles of this Issue 3/2010

Endocrine Pathology 3/2010 Go to the issue

OriginalPaper

VEGF and CD31 Association in Pituitary Adenomas

OriginalPaper

The Frequency of Selected Polymorphic Variants of the RET Gene in Patients with Medullary Thyroid Carcinoma and in the General Population of Central Poland

OriginalPaper

Parafibromin and APC as Screening Markers for Malignant Potential in Atypical Parathyroid Adenomas

OriginalPaper

Higher Frequency of Thyroid Tumors in the Right Lobe

Report

Predominant Brenner Tumor Combined with Struma Ovarii Containing a Papillary Microcarcinoma Associated with Benign Peritoneal Strumosis: Report of a Case and Histologic Features

Report

Ghrelin-Producing Well-Differentiated Neuroendocrine Tumor (Carcinoid) of Tailgut Cyst. Morphological, Immunohistochemical, Ultrastructural, and RT-PCR Study of a Case and Review of the Literature
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits